Ophirex Publishes Phase 2 Data in BMJ Global Health from the First Use of Varespladib to Treat Venomous Snakebite Victims

  • Charles Gerardo

Press/Media

Period23 Oct 2024

Media coverage

4

Media coverage

  • TitleOphirex Publishes Phase 2 Data in BMJ Global Health from the First Use of Varespladib to Treat Venomous Snakebite Victims
    Media name/outletBusiness Wire
    Country/TerritoryUnited States
    Date23/10/24
    URLct.moreover.com/?a=55100639743&p=1gw&v=1&x=U4Jtw2tkYxHeBi3mVgMJvw
    PersonsCharles Gerardo
  • TitleOphirex Publishes Phase 2 Data in BMJ Global Health from the First Use of Varespladib to Treat Venomous Snakebite Victims; Efficacy signal observed in subgroup of victims treated within five hours of bite reinforces critical importance of timely treatment
    Media name/outletBusiness Wire
    Country/TerritoryUnited States
    Date23/10/24
    PersonsCharles Gerardo
  • TitleOphirex Publishes Phase 2 Data in BMJ Global Health from the First Use of Varespladib to Treat Venomous Snakebite Victims
    Media name/outletAPNews.com
    Country/TerritoryUnited States
    Date23/10/24
    URLct.moreover.com/?a=55100603333&p=1gw&v=1&x=B-Q8d1yUdHoPnINSW6PmzA
    PersonsCharles Gerardo
  • TitleOphirex Publishes Phase 2 Data in BMJ Global Health from the First Use of Varespladib to Treat Venomous Snakebite Victims
    Media name/outletLe Lezard.com
    Country/TerritoryCanada
    Date23/10/24
    URLct.moreover.com/?a=55100644040&p=1gw&v=1&x=8ldo8KhF861PwU-qNMxTIw
    PersonsCharles Gerardo